Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Cohort Study of Multiple Doses of Cavatak™ (Coxsackie Virus A21) Given Intravenously to Stage IV Solid Tumour Cancer Patients Bearing ICAM-1 With or Without DAF Expressing Tumours (PSX-X04)

Next Previous
X
Search
Trial Profile

A Phase I, Open-Label, Cohort Study of Multiple Doses of Cavatak™ (Coxsackie Virus A21) Given Intravenously to Stage IV Solid Tumour Cancer Patients Bearing ICAM-1 With or Without DAF Expressing Tumours (PSX-X04)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gebasaxturev (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Malignant melanoma; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Viralytics

    • Most Recent Events

    • 09 Apr 2013 Primary endpoint `patient tolerability' has been met, according to a Viralytics media release.
    • 09 Apr 2013 Results reported in a Viralytics media release.
    • 09 Nov 2012 Results were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in November 2012, according to a Viralytics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top